Tags

Type your tag names separated by a space and hit enter

Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms.

Abstract

The endocannabinoids are a family of bioactive lipids that activate CB1 cannabinoid receptors in the brain and exert intense emotional and cognitive effects. Here, we have examined the role of endocannabinoid signaling in psychotic states by measuring levels of the endocannabinoid anandamide in cerebrospinal fluid (CSF) of acute paranoid-type schizophrenic patients. We found that CSF anandamide levels are eight-fold higher in antipsychotic-naive first-episode paranoid schizophrenics (n = 47) than healthy controls (n = 84), dementia patients (n = 13) or affective disorder patients (n = 22). Such an alteration is absent in schizophrenics treated with 'typical' antipsychotics (n = 37), which antagonize dopamine D2-like receptors, but not in those treated with 'atypical' antipsychotics (n = 34), which preferentially antagonize 5HT(2A) receptors. Furthermore, we found that, in nonmedicated acute schizophrenics, CSF anandamide is negatively correlated with psychotic symptoms (rS = -0.452, P = 0.001). The results suggest that anandamide elevation in acute paranoid schizophrenia may reflect a compensatory adaptation to the disease state.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Pharmacology, University of California, Irvine, CA, USA.

    , , , , , ,

    Source

    MeSH

    Adult
    Aged
    Aged, 80 and over
    Arachidonic Acids
    Cohort Studies
    Endocannabinoids
    Female
    Humans
    Male
    Middle Aged
    Polyunsaturated Alkamides
    Psychotic Disorders
    Schizophrenia
    Statistics, Nonparametric

    Pub Type(s)

    Comparative Study
    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    15354183

    Citation

    Giuffrida, Andrea, et al. "Cerebrospinal Anandamide Levels Are Elevated in Acute Schizophrenia and Are Inversely Correlated With Psychotic Symptoms." Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, vol. 29, no. 11, 2004, pp. 2108-14.
    Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29(11):2108-14.
    Giuffrida, A., Leweke, F. M., Gerth, C. W., Schreiber, D., Koethe, D., Faulhaber, J., ... Piomelli, D. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 29(11), pp. 2108-14.
    Giuffrida A, et al. Cerebrospinal Anandamide Levels Are Elevated in Acute Schizophrenia and Are Inversely Correlated With Psychotic Symptoms. Neuropsychopharmacology. 2004;29(11):2108-14. PubMed PMID: 15354183.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. AU - Giuffrida,Andrea, AU - Leweke,F Markus, AU - Gerth,Christoph W, AU - Schreiber,Daniela, AU - Koethe,Dagmar, AU - Faulhaber,Johannes, AU - Klosterkötter,Joachim, AU - Piomelli,Daniele, PY - 2004/9/9/pubmed PY - 2005/1/12/medline PY - 2004/9/9/entrez SP - 2108 EP - 14 JF - Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology JO - Neuropsychopharmacology VL - 29 IS - 11 N2 - The endocannabinoids are a family of bioactive lipids that activate CB1 cannabinoid receptors in the brain and exert intense emotional and cognitive effects. Here, we have examined the role of endocannabinoid signaling in psychotic states by measuring levels of the endocannabinoid anandamide in cerebrospinal fluid (CSF) of acute paranoid-type schizophrenic patients. We found that CSF anandamide levels are eight-fold higher in antipsychotic-naive first-episode paranoid schizophrenics (n = 47) than healthy controls (n = 84), dementia patients (n = 13) or affective disorder patients (n = 22). Such an alteration is absent in schizophrenics treated with 'typical' antipsychotics (n = 37), which antagonize dopamine D2-like receptors, but not in those treated with 'atypical' antipsychotics (n = 34), which preferentially antagonize 5HT(2A) receptors. Furthermore, we found that, in nonmedicated acute schizophrenics, CSF anandamide is negatively correlated with psychotic symptoms (rS = -0.452, P = 0.001). The results suggest that anandamide elevation in acute paranoid schizophrenia may reflect a compensatory adaptation to the disease state. SN - 0893-133X UR - https://www.unboundmedicine.com/medline/citation/15354183/Cerebrospinal_anandamide_levels_are_elevated_in_acute_schizophrenia_and_are_inversely_correlated_with_psychotic_symptoms_ L2 - http://dx.doi.org/10.1038/sj.npp.1300558 DB - PRIME DP - Unbound Medicine ER -